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OBJECTIVES: Worldwide there is an increase of antibiotics
resistance which could be managed. For such purpose the project
Slovak Medical Dialog (S–MedDial) was established within an
international cooperation of General Health Insurance Fund,
Brussels Gentile Insurance Companies Association, Bratislava
municipality, Pharmaceutical Faculty and Civil Society Health
City. Aim was to initiate the communication between health
insurance fund and general practitioner in order to support
an effective antibiotics prescription and to improve mutual
co-operation. METHODS: The analysis of prescription habits of
pediatricians in general practice for respiratory infections was
based on a) prospective data collection according to the registers
about treatment in one month period, and b) retrospective analy-
sis of health insurance data. Individual regions were analyzed in
regards the antibiotics resistance trends in cooperation with
microbiologists from selected regions. RESULTS: Sixty-six pedia-
tricians in Slovakia participated on this multicentric prospec-
tive prescription study, which started in November 2003.
Co-operating practitioners ﬁlled 11 518 protocols in y.2003, 14
289 in y.2005 and 14 537 protocols in y.2006. General Health
Insurance Fund data for two 6-month periods were analyzed.
Total ratio of antibiotic treatment was 52% in y.2003 and 55%
in y.2005. Antibiotic consumption was from 1, 4 to 12, 9 DDD
per patient. System of comparison of prescription proﬁles was
created where the ranking scale of 0–10 was used and each
practitioner received an individual feedback with many quanti-
tative and qualitative indicators for two monitored periods. Indi-
vidual feedback, information about resistance and cost trends
were provided to the pediatricians within the quality educational
rounds with their very positive reaction. Today the project was
revived and the 2006 data are processed. CONCLUSION:
Through providing of individual feedback the prescription of
different drug groups could be inﬂuenced not only concerning
costs but quality as well (i.e. inﬂuencing the adverse evolution of
bacterial pathogens resistance to antibiotics).
RESPIRATORY DISORDERS—Methods and Concepts
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OBJECTIVES: To evaluate a pharmaceutical care programme for
COPD patients in a hospital setting including patient education.
METHODS: Patients with COPD were enrolled in a prospective
study during hospital stay (average 7, 6 days) and followed a
structured pharmaceutical care programme including three train-
ing sessions of a total average time of 83 minutes concerning the
disease itself, drug therapy, breathing exercises, nutrition and in
some cases smoking cessation. Data of patients were collected on
3 occasions (admission, after discharge, follow up 6 months after
release from hospital) to investigate the effects of pharmaceutical
care including health related quality of life (assessed by generic
questionnaire SF-36 an COPD-speciﬁc questionnaire St George’s
Respiratory Questionnaire, SGRQ), patient knowledge, inhala-
tion technique and reduction of hospital days as well as number
of re-admissions. RESULTS: One-hundred, ﬁve patients (47
male, 58 female, mean age 69.9, SD 6.6) who had received a
structured pharmaceutical care programme showed improved
scores in a pre-post comparison with regard to knowledge, self
management, inhalation techniques and quality of life (SF-36,
SGRQ). Compared with data from a pneumonological ward and
all other hospital units the number of hospital days as well as the
number of re-admissions were signiﬁcantly lower for the study
population. The follow-up 6 months after hospital release
revealed that the level of knowledge was difﬁcult to maintain
especially for those patients who did not receive pharmaceutical
care in their community pharmacy. CONCLUSION: Structured
pharmaceutical care programmes are effective even during a
short stay in hospital with regard to several outcome parameters.
However, the results can only be maintained when there is an
outreach into ambulatory care through community pharmacies.
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OBJECTIVES: To quantify community acquired pneumonia
(CAP) treatment outcomes and costs from a managed care per-
spective by the level of macrolide resistance corresponding to
the Metropolitan Statistical Area (MSA) where patients lived.
METHODS: A retrospective analysis was conducted using the
i3 Magniﬁ database (May 2000–May 2005) and the Prospec-
tive Resistant Organism Tracking and Epidemiology for the
Ketolide Telithromycin (PROTEKT) Database. Continuously
enrolled patients aged 18 years and older residing in MSAs
with PROTEKT data that had an outpatient CAP-related
ICD-9 code and with one antibiotic pharmacy claim within 7
days were included. Patients were excluded for having a prior
conditions or drug treatment which could mimic CAP or pre-
cipitate infections, or for recent hospitalizations. Treatment
costs by level of resistance in the patient’s MSA and by treat-
ment outcome were measured and adjusted for differences in
baseline patient characteristics. RESULTS: The study identiﬁed
9965 CAP patients (average age of 47.6 yrs, 52.1% male). The
majority (56.3%) resided in an MSA with macrolide resistance
rates <25%. The overall treatment success rate was 81.6%,
with success rates of 82.5% and 80.5% for MSAs with resis-
tance levels <25% and 25% respectively (P < 0.001). Treat-
ment failure resulting in hospitalization was higher in resistance
areas 25% at 13.1% versus 8.0% in areas with resistance
<25% (P < 0.001). Average adjusted treatment costs were $623
higher for those treated in areas with resistance levels 25%
than those treated in areas where resistance was <25%. Treat-
ment success was associated with average adjusted costs that
were $1478 less than those whose initial treatment failed, con-
trolling for level resistance (P < 0.001). CONCLUSION: This
study observed an association with community level macrolide
resistance and treatment and economic outcomes. Treatment
failure rates costs were higher for CAP patients treated in areas
with macrolide resistance rates 25% than those treated in
areas where resistance was 25%.
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